ロード中...
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
BACKGROUND: Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors. This publication describes the safety profile of onartuzumab in patients with solid tumors usi...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4596876/ https://ncbi.nlm.nih.gov/pubmed/26445503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0139679 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|